<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240915</url>
  </required_header>
  <id_info>
    <org_study_id>B3041001</org_study_id>
    <secondary_id>2010-022766-27</secondary_id>
    <nct_id>NCT01240915</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Athersys, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MultiStem(r) is a new biological product, manufactured from human stem cells obtained from
      adult bone marrow or other nonembryonic tissue sources. Factors expressed by MultiStem cells
      are believed to reduce inflammation and regulate immune system function, protect damaged or
      injured cells and tissue, promote formation of new blood vessels, and augment tissue repair
      and healing. MultiStem cell treatment resulted in significant efficacy in a mouse model of
      Graft versus Host Disease with almost complete reversal of gastrointestinal pathology
      (similar to pathology that would be expected in Ulcerative Colitis). These data, together
      with safety data generated in 2 other clinical trials, suggest that MultiStem has the
      potential to be a new treatment option for patients with ulcerative colitis. This is the
      first study of MultiStem in this patient population and will cautiously explore the
      safety/toleration and potential benefit of this new treatment in patients with moderate to
      severe disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)</measure>
    <time_frame>Baseline up to Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment-Emergent AEs by Severity</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16</measure>
    <time_frame>Baseline, Week 12, Week 16</time_frame>
    <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>The total number of participants with laboratory test abnormalities with or without regard to baseline abnormality was assessed. Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte sedimentation rate); chemistry (blood urea nitrogen and creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy (only if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase); other (follicle-stimulating hormone, human chorionic gonadotropin, stool microbiology, creatinine kinase, direct bilirubin, indirect bilirubin, gamma-glutamyl transferase, international normalized ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Vital Signs Findings</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Vital signs assessment included pulse rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Criteria for vital sign values meeting potential clinical concern included: SBP &lt;90 millimeters of mercury (mm Hg) and &gt;=30 mm Hg increase/decrease from baseline, DBP &lt;50 mm Hg and &gt;=20 mm Hg increase/decrease from baseline, pulse rate &lt;40 or &gt;120 beats per minute (bpm),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16</measure>
    <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
    <description>Fecal calprotectin, a very stable marker, is a 36kDa calcium and zinc binding protein which is neutrophil-derived. It represents 60% of cytosolic proteins in granulocytes and is a measurement of neutrophil migration to the gastrointestinal tract.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16</measure>
    <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
    <description>CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16</measure>
    <time_frame>Week 4, 8, 12 and 16</time_frame>
    <description>Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Endoscopic Remission at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding). Endoscopic remission is defined as modified Baron Endoscopic Score equal to 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical remission is defined as a total Mayo score of 2 points or lower, with no individual subscores exceeding 1 point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16</measure>
    <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
    <description>Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes). A decrease from baseline score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Response at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Endoscopic response is defined as a decrease in modified Baron endoscopic score from baseline of at least 2 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Response at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical response is defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Mayo Scores at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis, with total score ranging from 0 to 12. It consists of 4 subscores (stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment [PGA]), each graded from 0 to 3, with higher scores indicating more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16</measure>
    <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
    <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo Score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher scores indicate more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Biopsy Histology Scores at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>A 15 to 25 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>Patient-reported diary data assessed the number of bowel movements (BM) per day when not having a flare and the presence of blood in the stools (rectal bleeding [RB]), if any.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 &amp; 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once every 7 days for 1- 3 doses</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiStem low dose</intervention_name>
    <description>1-3 doses</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose at week 8</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiStem low dose</intervention_name>
    <description>Single dose at week 8</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose Day 1</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiStem high dose</intervention_name>
    <description>Single dose Day 1</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose at week 8</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiStem high dose</intervention_name>
    <description>Single dose at week 8</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose Day 1</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiStem high dose</intervention_name>
    <description>Single dose Day 1</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single dose at week 8</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiStem high dose</intervention_name>
    <description>Single dose at week 8</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a documented diagnosis of ulcerative colitis at least 6 months
             prior to screening.

          -  Subjects must have active moderate-to-severe ulcerative colitis based on Mayo score.

          -  Subjects must have Modified Baron endoscopic score of at least 2 determined within 7
             days of first dosing.

          -  Subjects must have failed or be intolerant (as determined by the investigator) of at
             least one of the following treatments for UC: Oral corticosteroids, azathioprine or
             6-mercaptopurine (6-MP), or anti-tumor necrosis factor (TNF) therapy, eg, infliximab
             or adalimumab.

          -  Subjects must be on stable steroid doses.

        Exclusion Criteria:

          -  Subjects who have abnormal organ and marrow function.

          -  Subjects with a diagnosis of indeterminate colitis, or clinical findings suggestive of
             Crohn's disease.

          -  Subjects who meet Truelove-Witts criteria for severe ulcerative colitis.

          -  Subjects receiving or who are expected to receive Infliximab or other biologic
             treatment within 8 weeks of the Day 1 study visit.

          -  Subjects receiving or who are expected to receive Cyclosporine, mycophenolate, or
             tacrolimus within 4 weeks of the Day 1 study visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USCF Endoscopy Unit at Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of the Rockies</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Gastroenterology Associates, LLC</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arapahoe Gastroenterology, PC</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group, PC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of Clearwater</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Endoscopy Center</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Endoscopy</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center, Digestive Health</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Healthcare Outpatient Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastroenterology Group, PC - Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopic Microsurgery Associates, PA</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Michigan, LLC</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utica Surgery Center</name>
      <address>
        <city>Utica</city>
        <state>Michigan</state>
        <zip>48317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgery Center of Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive and Liver Diseases, Inc.</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Present, Chapman, Steinlauf and Marion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asher Kornbluth, MD PC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastroenterology and Hepatology, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Internal Medicine Consultants, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University University Baptist Medical Center - Internal Medicine</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-1375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Leigh Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme / Gastroenterology</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Alberta Clinical Trials and Research Center</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zeidler Ledcor Centre - University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pandy Kalman Megyei Korhaz, III. sz. Belosztaly-Gasztroenterologia</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolina Korhaz Rendelointezet, Belgyogyaszat</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolna Megyei Balassa Janos Korhaz / II. Belgyogyaszat</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologicke a hepatologicke oddelenie, V. interna klinika LFUK a UN Bratislava, Ruzinov</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologicka ambulancia, GEA s.r.o.</name>
      <address>
        <city>Trnava</city>
        <zip>917 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset Medicinkliniken</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, GastroCentrum Medicin</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset, Mag tarmmottagningen</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3041001&amp;StudyName=A%20Study%20To%20Investigate%20The%20Safety%20And%20Possible%20Clinical%20Benefit%20Of%20Multistem%28r%29%20In%20Patients%20With%20Moderate%20To%20Severe%20Ulcerative%20Colit</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <results_first_submitted>November 20, 2015</results_first_submitted>
  <results_first_submitted_qc>January 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2016</results_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety efficacy MultiStem(r) moderate to severe Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Placebo, MultiStem 300</title>
          <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Placebo, MultiStem 750</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1: MultiStem 300, Placebo</title>
          <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
          <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 2: MultiStem 750, Placebo</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 3: MultiStem 750, MultiStem 750</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 3: MultiStem 750, Placebo</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 3: Placebo, MultiStem 750</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 3: Placebo, Placebo</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="25"/>
                <participants group_id="P8" count="19"/>
                <participants group_id="P9" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="15"/>
                <participants group_id="P9" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set consisted of all participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Placebo, MultiStem 300</title>
          <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Placebo, MultiStem 750</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1: MultiStem 300 or MultiStem 300 (x3), Placebo</title>
          <description>Participants received either a single dose of MultiStem 300 Million Cells infusion on Day 1 or 3 doses on Day 1, Week 1, and Week 2; followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 2: MultiStem 750, Placebo</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3: MultiStem 750, MultiStem 750</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 3: MultiStem 750, Placebo</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 3: Placebo, MultiStem 750</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 3: Placebo, Placebo</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="23"/>
            <count group_id="B6" value="25"/>
            <count group_id="B7" value="19"/>
            <count group_id="B8" value="21"/>
            <count group_id="B9" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="7.1"/>
                    <measurement group_id="B2" value="52.0" spread="7.0"/>
                    <measurement group_id="B3" value="49.3" spread="14.1"/>
                    <measurement group_id="B4" value="40.0" spread="14.0"/>
                    <measurement group_id="B5" value="43.4" spread="12.8"/>
                    <measurement group_id="B6" value="38.8" spread="13.4"/>
                    <measurement group_id="B7" value="39.8" spread="12.5"/>
                    <measurement group_id="B8" value="42.5" spread="15.7"/>
                    <measurement group_id="B9" value="42.2" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8</title>
        <description>Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint. Baseline observation carried forward (BOCF) was used for treatment failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MultiStem</title>
            <description>All participants who received MultiStem 750 Million Cells infusion on Day 1 in Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>Pooled Placebo</title>
            <description>All participants who received placebo infusion on Day 1 in Cohort 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Endoscopic Score (as Measured by Modified Baron Score) at Week 8</title>
          <description>Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding).</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint. Baseline observation carried forward (BOCF) was used for treatment failures.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="1.104"/>
                    <measurement group_id="O2" value="3.10" spread="1.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="1.134"/>
                    <measurement group_id="O2" value="-0.30" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.223</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4</title>
        <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MultiStem</title>
            <description>All participants who received MultiStem 750 Million Cells infusion on Day 1 in Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>Pooled Placebo</title>
            <description>All participants who received placebo infusion on Day 1 in Cohort 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 4</title>
          <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.942"/>
                    <measurement group_id="O2" value="1.23" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.943"/>
                    <measurement group_id="O2" value="-0.38" spread="0.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 8</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.161</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8</title>
        <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled MultiStem</title>
            <description>All participants who received MultiStem 750 Million Cells infusion on Day 1 in Cohort 3.</description>
          </group>
          <group group_id="O2">
            <title>Pooled Placebo</title>
            <description>All participants who received placebo infusion on Day 1 in Cohort 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 8</title>
          <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="1.051"/>
                    <measurement group_id="O2" value="-0.43" spread="0.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 8</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.174</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
          <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="16"/>
                    <measurement group_id="O9" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)</title>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent AEs by System Organ Class (SOC)</title>
          <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BLOOD AND LYMPHATIC SYSTEM DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CARDIAC DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EAR AND LABYRINTH DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ENDOCRINE DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EYE DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GASTROINTESTINAL DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GENERAL DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMMUNE SYSTEM DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INFECTIONS AND INFESTATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INVESTIGATIONS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>METABOLISM AND NUTRITION DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NERVOUS SYSTEM DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSYCHIATRIC DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RENAL AND URINARY DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SURGICAL AND MEDICAL PROCEDURES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASCULAR DISORDERS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment-Emergent AEs by Severity</title>
        <description>The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment-Emergent AEs by Severity</title>
          <description>The intensity grades were defined as follows: mild=does not interfere with participant's usual function; moderate=interferes to some extent with participant's usual function; severe=interferes significantly with participant's usual function.</description>
          <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="61"/>
                    <measurement group_id="O7" value="35"/>
                    <measurement group_id="O8" value="56"/>
                    <measurement group_id="O9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16</title>
        <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
        <time_frame>Baseline, Week 12, Week 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rectal Bleeding Mayo Subscore at Week 12 and Week 16</title>
          <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo subscores for rectal bleeding range from 0 to 3, with higher scores indicating more severe disease.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12 (n=0,0,0,0,0,22,25,17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O6" value="-0.77" spread="0.869"/>
                    <measurement group_id="O7" value="-0.64" spread="1.114"/>
                    <measurement group_id="O8" value="-0.53" spread="0.874"/>
                    <measurement group_id="O9" value="-0.47" spread="0.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16 (n=2,3,2,4,6,21,24,17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="0.707"/>
                    <measurement group_id="O2" value="-1.00" spread="1.000"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                    <measurement group_id="O4" value="0.00" spread="0.816"/>
                    <measurement group_id="O5" value="-0.60" spread="1.140"/>
                    <measurement group_id="O6" value="-0.57" spread="0.978"/>
                    <measurement group_id="O7" value="-0.92" spread="1.100"/>
                    <measurement group_id="O8" value="-0.47" spread="0.874"/>
                    <measurement group_id="O9" value="-0.58" spread="0.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Test Abnormalities</title>
        <description>The total number of participants with laboratory test abnormalities with or without regard to baseline abnormality was assessed. Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte sedimentation rate); chemistry (blood urea nitrogen and creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy (only if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase); other (follicle-stimulating hormone, human chorionic gonadotropin, stool microbiology, creatinine kinase, direct bilirubin, indirect bilirubin, gamma-glutamyl transferase, international normalized ratio.</description>
        <time_frame>Baseline up to Week 24</time_frame>
        <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities</title>
          <description>The total number of participants with laboratory test abnormalities with or without regard to baseline abnormality was assessed. Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes, erythrocyte sedimentation rate); chemistry (blood urea nitrogen and creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein; urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, microscopy (only if urine dipstick was positive for blood, protein, nitrites or leukocyte esterase); other (follicle-stimulating hormone, human chorionic gonadotropin, stool microbiology, creatinine kinase, direct bilirubin, indirect bilirubin, gamma-glutamyl transferase, international normalized ratio.</description>
          <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal/Abnormal Baseline(n=2,3,2,4,6,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Baseline (n=2,3,2,4,6,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="12"/>
                    <measurement group_id="O9" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal Baseline (n=2,3,2,2,3,22,19,15,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially Clinically Significant Vital Signs Findings</title>
        <description>Vital signs assessment included pulse rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Criteria for vital sign values meeting potential clinical concern included: SBP &lt;90 millimeters of mercury (mm Hg) and &gt;=30 mm Hg increase/decrease from baseline, DBP &lt;50 mm Hg and &gt;=20 mm Hg increase/decrease from baseline, pulse rate &lt;40 or &gt;120 beats per minute (bpm),</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Vital Signs Findings</title>
          <description>Vital signs assessment included pulse rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Criteria for vital sign values meeting potential clinical concern included: SBP &lt;90 millimeters of mercury (mm Hg) and &gt;=30 mm Hg increase/decrease from baseline, DBP &lt;50 mm Hg and &gt;=20 mm Hg increase/decrease from baseline, pulse rate &lt;40 or &gt;120 beats per minute (bpm),</description>
          <population>The safety analysis population consisted of all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine Pulse Rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine Pulse Rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP &gt;=30 mm Hg Increase From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &gt;=20 mm Hg Increase From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP &gt;=30 mm Hg Decrease From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP &gt;=20 mm Hg Decrease From Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16</title>
        <description>Fecal calprotectin, a very stable marker, is a 36kDa calcium and zinc binding protein which is neutrophil-derived. It represents 60% of cytosolic proteins in granulocytes and is a measurement of neutrophil migration to the gastrointestinal tract.</description>
        <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change From Baseline in Fecal Calprotectin at Weeks 4, 8, 12, and 16</title>
          <description>Fecal calprotectin, a very stable marker, is a 36kDa calcium and zinc binding protein which is neutrophil-derived. It represents 60% of cytosolic proteins in granulocytes and is a measurement of neutrophil migration to the gastrointestinal tract.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2,3,1,4,5,21,23,19,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="690.7549" spread="17"/>
                    <measurement group_id="O2" value="1189.8169" spread="22"/>
                    <measurement group_id="O3" value="739.2300">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="898.2758" spread="89"/>
                    <measurement group_id="O5" value="874.1363" spread="1462"/>
                    <measurement group_id="O6" value="576.5796" spread="237"/>
                    <measurement group_id="O7" value="476.1504" spread="222"/>
                    <measurement group_id="O8" value="513.2139" spread="208"/>
                    <measurement group_id="O9" value="821.1953" spread="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=2,3,1,3,5,20,21,18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6297" spread="50"/>
                    <measurement group_id="O2" value="1.8680" spread="103"/>
                    <measurement group_id="O3" value="2.0264">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="2.0549" spread="112"/>
                    <measurement group_id="O5" value="1.0940" spread="91"/>
                    <measurement group_id="O6" value="1.2196" spread="158"/>
                    <measurement group_id="O7" value="0.8179" spread="314"/>
                    <measurement group_id="O8" value="1.0541" spread="166"/>
                    <measurement group_id="O9" value="0.6722" spread="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=1,2,1,3,2,18,20,17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4504">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="2.4559" spread="51"/>
                    <measurement group_id="O3" value="2.6199">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="0.5744" spread="52"/>
                    <measurement group_id="O5" value="0.3282" spread="2"/>
                    <measurement group_id="O6" value="1.0704" spread="220"/>
                    <measurement group_id="O7" value="0.7462" spread="235"/>
                    <measurement group_id="O8" value="0.8598" spread="227"/>
                    <measurement group_id="O9" value="0.3479" spread="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n=0,0,0,0,0,20,21,17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O6" value="0.9947" spread="171"/>
                    <measurement group_id="O7" value="0.8269" spread="310"/>
                    <measurement group_id="O8" value="0.8788" spread="293"/>
                    <measurement group_id="O9" value="0.5279" spread="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16 (n=2,3,1,4,4,18,18,16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1672" spread="49"/>
                    <measurement group_id="O2" value="0.7679" spread="32"/>
                    <measurement group_id="O3" value="1.1956">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="0.4459" spread="139"/>
                    <measurement group_id="O5" value="0.2474" spread="4517"/>
                    <measurement group_id="O6" value="0.6473" spread="277"/>
                    <measurement group_id="O7" value="0.8486" spread="149"/>
                    <measurement group_id="O8" value="0.5473" spread="309"/>
                    <measurement group_id="O9" value="0.5275" spread="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.48</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.38</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16</title>
        <description>CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria.</description>
        <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Fold Change From Baseline in C-Reactive Protein (CRP) at Weeks 4, 8, 12, and 16</title>
          <description>CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>fold change</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2,3,2,4,6,22,25,19,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.272" spread="45"/>
                    <measurement group_id="O2" value="1.527" spread="118"/>
                    <measurement group_id="O3" value="0.229" spread="34"/>
                    <measurement group_id="O4" value="0.578" spread="37"/>
                    <measurement group_id="O5" value="0.180" spread="74"/>
                    <measurement group_id="O6" value="0.613" spread="339"/>
                    <measurement group_id="O7" value="0.542" spread="236"/>
                    <measurement group_id="O8" value="0.397" spread="157"/>
                    <measurement group_id="O9" value="0.453" spread="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=2,3,2,3,6,21,25,18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.289" spread="9"/>
                    <measurement group_id="O2" value="0.555" spread="82"/>
                    <measurement group_id="O3" value="1.937" spread="42"/>
                    <measurement group_id="O4" value="1.285" spread="60"/>
                    <measurement group_id="O5" value="1.446" spread="54"/>
                    <measurement group_id="O6" value="0.891" spread="147"/>
                    <measurement group_id="O7" value="0.764" spread="140"/>
                    <measurement group_id="O8" value="0.999" spread="103"/>
                    <measurement group_id="O9" value="0.588" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=1,3,1,3,5,21,25,19,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.390">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="0.745" spread="49"/>
                    <measurement group_id="O3" value="2.331">Only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="1.172" spread="20"/>
                    <measurement group_id="O5" value="1.555" spread="31"/>
                    <measurement group_id="O6" value="1.189" spread="146"/>
                    <measurement group_id="O7" value="0.759" spread="207"/>
                    <measurement group_id="O8" value="1.200" spread="113"/>
                    <measurement group_id="O9" value="0.623" spread="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n=0,0,0,0,0,21,24,17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O6" value="0.937" spread="211"/>
                    <measurement group_id="O7" value="0.710" spread="365"/>
                    <measurement group_id="O8" value="0.782" spread="149"/>
                    <measurement group_id="O9" value="0.373" spread="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16 (n=2,3,2,4,5,20,24,17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.956" spread="164"/>
                    <measurement group_id="O2" value="0.481" spread="56"/>
                    <measurement group_id="O3" value="0.606" spread="248"/>
                    <measurement group_id="O4" value="0.869" spread="14"/>
                    <measurement group_id="O5" value="1.184" spread="54"/>
                    <measurement group_id="O6" value="0.776" spread="156"/>
                    <measurement group_id="O7" value="0.425" spread="176"/>
                    <measurement group_id="O8" value="0.612" spread="133"/>
                    <measurement group_id="O9" value="0.417" spread="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.17</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>2.75</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.63</ci_lower_limit>
            <ci_upper_limit>4.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.96</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.98</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>2.30</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.52</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.51</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16</title>
        <description>Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes).</description>
        <time_frame>Week 4, 8, 12 and 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rectal Bleeding Mayo Subscore of Zero at Weeks 4, 8, 12, and 16</title>
          <description>Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes).</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="52.2"/>
                    <measurement group_id="O7" value="28.0"/>
                    <measurement group_id="O8" value="31.6"/>
                    <measurement group_id="O9" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="47.8"/>
                    <measurement group_id="O7" value="36.0"/>
                    <measurement group_id="O8" value="31.6"/>
                    <measurement group_id="O9" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O6" value="60.9"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="47.4"/>
                    <measurement group_id="O9" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="47.8"/>
                    <measurement group_id="O7" value="48.0"/>
                    <measurement group_id="O8" value="36.8"/>
                    <measurement group_id="O9" value="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>2.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>5.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.21</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Endoscopic Remission at Week 8</title>
        <description>Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding). Endoscopic remission is defined as modified Baron Endoscopic Score equal to 0.</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Endoscopic Remission at Week 8</title>
          <description>Modified Baron Score is an instrument designed to measure endoscopic activity of ulcerative colitis. It classifies the mucosal inflammation in 4 grades (0=normal, 1=granular mucosa with an abnormal vascular pattern, 2=friable mucosa, 3=microulceration with spontaneous bleeding, 4=gross ulceration with spontaneous bleeding). Endoscopic remission is defined as modified Baron Endoscopic Score equal to 0.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="4.3"/>
                    <measurement group_id="O7" value="4.0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>3.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Clinical Remission at Week 8</title>
        <description>Clinical remission is defined as a total Mayo score of 2 points or lower, with no individual subscores exceeding 1 point.</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Remission at Week 8</title>
          <description>Clinical remission is defined as a total Mayo score of 2 points or lower, with no individual subscores exceeding 1 point.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="8.0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16</title>
        <description>Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes). A decrease from baseline score indicates improvement.</description>
        <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Decrease From Baseline of at Least 1 Point in Rectal Bleeding Mayo Subscore at Weeks 4, 8, 12, and 16</title>
          <description>Mayo subscores for rectal bleeding range from 0 to 3 (0=no blood seen; 1=streaks of blood with stool less than half the time; 2=obvious blood with stool most of the time; 3=blood alone passes). A decrease from baseline score indicates improvement.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="43.5"/>
                    <measurement group_id="O7" value="48.0"/>
                    <measurement group_id="O8" value="21.1"/>
                    <measurement group_id="O9" value="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="40.0"/>
                    <measurement group_id="O6" value="34.8"/>
                    <measurement group_id="O7" value="48.0"/>
                    <measurement group_id="O8" value="31.6"/>
                    <measurement group_id="O9" value="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O6" value="54.5"/>
                    <measurement group_id="O7" value="60.0"/>
                    <measurement group_id="O8" value="41.2"/>
                    <measurement group_id="O9" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="60.0"/>
                    <measurement group_id="O6" value="47.6"/>
                    <measurement group_id="O7" value="58.3"/>
                    <measurement group_id="O8" value="35.3"/>
                    <measurement group_id="O9" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.27</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>3.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.38</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.47</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Endoscopic Response at Week 8</title>
        <description>Endoscopic response is defined as a decrease in modified Baron endoscopic score from baseline of at least 2 points.</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Endoscopic Response at Week 8</title>
          <description>Endoscopic response is defined as a decrease in modified Baron endoscopic score from baseline of at least 2 points.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="8.7"/>
                    <measurement group_id="O7" value="8.0"/>
                    <measurement group_id="O8" value="10.5"/>
                    <measurement group_id="O9" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Clinical Response at Week 8</title>
        <description>Clinical response is defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1.</description>
        <time_frame>Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Response at Week 8</title>
          <description>Clinical response is defined as a decrease in total Mayo score from baseline of at least 3 points and at least 30 percent (%), with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore for rectal bleeding of 0 or 1.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4.3"/>
                    <measurement group_id="O7" value="24.0"/>
                    <measurement group_id="O8" value="15.8"/>
                    <measurement group_id="O9" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.30</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Mayo Scores at Week 8</title>
        <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis, with total score ranging from 0 to 12. It consists of 4 subscores (stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment [PGA]), each graded from 0 to 3, with higher scores indicating more severe disease.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Mayo Scores at Week 8</title>
          <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis, with total score ranging from 0 to 12. It consists of 4 subscores (stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy, and physician global assessment [PGA]), each graded from 0 to 3, with higher scores indicating more severe disease.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2,3,2,4,6,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="2.828"/>
                    <measurement group_id="O2" value="7.33" spread="1.155"/>
                    <measurement group_id="O3" value="8.50" spread="0.707"/>
                    <measurement group_id="O4" value="7.75" spread="0.957"/>
                    <measurement group_id="O5" value="7.50" spread="2.258"/>
                    <measurement group_id="O6" value="8.74" spread="1.839"/>
                    <measurement group_id="O7" value="8.48" spread="2.143"/>
                    <measurement group_id="O8" value="8.47" spread="1.806"/>
                    <measurement group_id="O9" value="8.14" spread="2.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=2,3,2,3,5,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.414" lower_limit="-1.84" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.00" spread="2.646" lower_limit="-2.32" upper_limit="-0.30"/>
                    <measurement group_id="O3" value="1.00" spread="1.414" lower_limit="-2.11" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.33" spread="0.577" lower_limit="-3.37" upper_limit="-1.15"/>
                    <measurement group_id="O5" value="-0.60" spread="0.894"/>
                    <measurement group_id="O6" value="-0.78" spread="2.088"/>
                    <measurement group_id="O7" value="-1.20" spread="2.872"/>
                    <measurement group_id="O8" value="-0.89" spread="2.132"/>
                    <measurement group_id="O9" value="-2.00" spread="2.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.513</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16</title>
        <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo Score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher scores indicate more severe disease.</description>
        <time_frame>Baseline, Weeks 4, 8, 12 and 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Partial Mayo Scores at Weeks 4, 8, 12, and 16</title>
          <description>Mayo Score is an instrument designed to measure disease activity of ulcerative colitis. Mayo Score ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease. A Partial Mayo Score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and calculated as the sum of 3 subscores (stool frequency, rectal bleeding and PGA) with each ranging from 0 to 3 (0=normal, 1=mild, 2=moderate, 3=severe). Higher scores indicate more severe disease.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=2,3,2,4,6,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" spread="2.121"/>
                    <measurement group_id="O2" value="5.33" spread="0.577"/>
                    <measurement group_id="O3" value="6.00" spread="1.414"/>
                    <measurement group_id="O4" value="5.75" spread="0.500"/>
                    <measurement group_id="O5" value="5.50" spread="1.378"/>
                    <measurement group_id="O6" value="6.22" spread="1.347"/>
                    <measurement group_id="O7" value="6.08" spread="1.605"/>
                    <measurement group_id="O8" value="6.00" spread="1.202"/>
                    <measurement group_id="O9" value="5.71" spread="1.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=2,3,2,3,5,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="0.000" lower_limit="-1.84" upper_limit="0.33"/>
                    <measurement group_id="O2" value="-2.00" spread="1.732" lower_limit="-2.32" upper_limit="-0.30"/>
                    <measurement group_id="O3" value="-0.50" spread="0.707" lower_limit="-2.11" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.67" spread="1.528" lower_limit="-3.37" upper_limit="-1.15"/>
                    <measurement group_id="O5" value="-0.40" spread="1.140"/>
                    <measurement group_id="O6" value="-1.00" spread="1.414"/>
                    <measurement group_id="O7" value="-0.96" spread="1.791"/>
                    <measurement group_id="O8" value="-1.16" spread="1.675"/>
                    <measurement group_id="O9" value="-1.24" spread="1.895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=2,3,2,3,5,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="1.414"/>
                    <measurement group_id="O2" value="-1.00" spread="1.732"/>
                    <measurement group_id="O3" value="0.50" spread="0.707"/>
                    <measurement group_id="O4" value="0.33" spread="0.577"/>
                    <measurement group_id="O5" value="-0.80" spread="1.095"/>
                    <measurement group_id="O6" value="-0.91" spread="1.756"/>
                    <measurement group_id="O7" value="-1.12" spread="2.472"/>
                    <measurement group_id="O8" value="-0.79" spread="1.653"/>
                    <measurement group_id="O9" value="-1.62" spread="2.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n=0,0,0,0,0,22,25,17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O2" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O3" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O4" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O5" value="NA">No participants were analyzed in this arm at Week 12.</measurement>
                    <measurement group_id="O6" value="-1.91" spread="1.974"/>
                    <measurement group_id="O7" value="-1.52" spread="2.312"/>
                    <measurement group_id="O8" value="-2.06" spread="2.135"/>
                    <measurement group_id="O9" value="-2.11" spread="2.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16 (2,3,2,4,5,21,24,17,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="0.707"/>
                    <measurement group_id="O2" value="-3.00" spread="3.000"/>
                    <measurement group_id="O3" value="-1.00" spread="2.828"/>
                    <measurement group_id="O4" value="-1.25" spread="3.403"/>
                    <measurement group_id="O5" value="-2.20" spread="1.924"/>
                    <measurement group_id="O6" value="-1.86" spread="2.081"/>
                    <measurement group_id="O7" value="-2.54" spread="2.621"/>
                    <measurement group_id="O8" value="-2.41" spread="2.181"/>
                    <measurement group_id="O9" value="-2.63" spread="2.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.345</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.77</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.418</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.666</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.645</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.705</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.656</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.635</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.692</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Biopsy Histology Scores at Week 8</title>
        <description>A 15 to 25 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Biopsy Histology Scores at Week 8</title>
          <description>A 15 to 25 centimeter (cm) biopsy sample of inflamed mucosal tissue was taken from the worst affected area and scored using the Riley Index. The Riley Index is a histologic scoring system for the assessment of the activity and severity of ulcerative colitis, ranging from 0 to 24. It consists of 6 histologic features (acute inflammatory cell infiltrate, crypt abscesses, mucin depletion, surface epithelial integrity, chronic inflammatory cell infiltrate, and crypt architectural irregularities), all scored on a 4-point scale (higher scores indicate more severe disease).</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline(n=2,3,2,4,5,22,24,18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="1.41"/>
                    <measurement group_id="O2" value="9.7" spread="3.79"/>
                    <measurement group_id="O3" value="11.0" spread="2.83"/>
                    <measurement group_id="O4" value="7.0" spread="3.92"/>
                    <measurement group_id="O5" value="10.8" spread="3.77"/>
                    <measurement group_id="O6" value="9.4" spread="4.37"/>
                    <measurement group_id="O7" value="10.4" spread="4.24"/>
                    <measurement group_id="O8" value="9.9" spread="4.17"/>
                    <measurement group_id="O9" value="9.7" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=2,3,1,3,5,21,24,15,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="4.95" lower_limit="-1.84" upper_limit="0.33"/>
                    <measurement group_id="O2" value="1.3" spread="1.15" lower_limit="-2.32" upper_limit="-0.30"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-2.11" upper_limit="0.18">No standard deviation was calculated, as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="-1.0" spread="1.73" lower_limit="-3.37" upper_limit="-1.15"/>
                    <measurement group_id="O5" value="-0.4" spread="2.07"/>
                    <measurement group_id="O6" value="1.4" spread="4.63"/>
                    <measurement group_id="O7" value="-1.0" spread="3.76"/>
                    <measurement group_id="O8" value="0.9" spread="4.09"/>
                    <measurement group_id="O9" value="-1.5" spread="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.753</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16</title>
        <description>Patient-reported diary data assessed the number of bowel movements (BM) per day when not having a flare and the presence of blood in the stools (rectal bleeding [RB]), if any.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Placebo, MultiStem 300</title>
            <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: MultiStem 300, Placebo</title>
            <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
            <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 3: MultiStem 750, MultiStem 750</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: MultiStem 750, Placebo</title>
            <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 3: Placebo, MultiStem 750</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 3: Placebo, Placebo</title>
            <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-Reported Rectal Bleeding up to Week 16</title>
          <description>Patient-reported diary data assessed the number of bowel movements (BM) per day when not having a flare and the presence of blood in the stools (rectal bleeding [RB]), if any.</description>
          <population>The full analysis set included all available observed data from all randomized participants who completed at least 1 infusion and were either withdrawn as a treatment failure, or had at least 1 valid post-dose measurement on a primary endpoint; n=the number of participants analyzed at that time point in the respective arms.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="25"/>
                <count group_id="O8" value="19"/>
                <count group_id="O9" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BM: Baseline(n=2,3,2,4,6,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.50" spread="4.950"/>
                    <measurement group_id="O2" value="8.00" spread="2.784"/>
                    <measurement group_id="O3" value="6.75" spread="2.475"/>
                    <measurement group_id="O4" value="11.75" spread="10.508"/>
                    <measurement group_id="O5" value="8.42" spread="3.089"/>
                    <measurement group_id="O6" value="7.50" spread="3.490"/>
                    <measurement group_id="O7" value="7.78" spread="3.781"/>
                    <measurement group_id="O8" value="7.50" spread="3.571"/>
                    <measurement group_id="O9" value="6.88" spread="4.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 1 (n=2,3,2,4,5,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="2.263" lower_limit="-1.84" upper_limit="0.33"/>
                    <measurement group_id="O2" value="-1.89" spread="1.766" lower_limit="-2.32" upper_limit="-0.30"/>
                    <measurement group_id="O3" value="4.15" spread="2.845" lower_limit="-2.11" upper_limit="0.18"/>
                    <measurement group_id="O4" value="-0.60" spread="2.177" lower_limit="-3.37" upper_limit="-1.15"/>
                    <measurement group_id="O5" value="0.40" spread="1.300"/>
                    <measurement group_id="O6" value="-0.42" spread="1.509"/>
                    <measurement group_id="O7" value="-0.59" spread="1.657"/>
                    <measurement group_id="O8" value="-0.56" spread="1.215"/>
                    <measurement group_id="O9" value="-0.81" spread="3.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 4 (n=2,2,2,3,5,23,23,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="3.435"/>
                    <measurement group_id="O2" value="-1.89" spread="5.101"/>
                    <measurement group_id="O3" value="2.36" spread="0.505"/>
                    <measurement group_id="O4" value="0.17" spread="2.038"/>
                    <measurement group_id="O5" value="1.31" spread="1.432"/>
                    <measurement group_id="O6" value="-0.81" spread="2.088"/>
                    <measurement group_id="O7" value="0.28" spread="3.956"/>
                    <measurement group_id="O8" value="-0.63" spread="1.856"/>
                    <measurement group_id="O9" value="-1.08" spread="2.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 8 (n=2,3,2,3,6,23,23,16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="3.771"/>
                    <measurement group_id="O2" value="-0.86" spread="3.517"/>
                    <measurement group_id="O3" value="3.18" spread="0.758"/>
                    <measurement group_id="O4" value="0.17" spread="2.754"/>
                    <measurement group_id="O5" value="0.41" spread="2.131"/>
                    <measurement group_id="O6" value="-0.89" spread="2.864"/>
                    <measurement group_id="O7" value="-1.15" spread="2.833"/>
                    <measurement group_id="O8" value="0.18" spread="2.531"/>
                    <measurement group_id="O9" value="-1.41" spread="3.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 12 (n=1,1,1,2,2,21,25,16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="1.43">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O3" value="1.57">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="-1.68" spread="2.374"/>
                    <measurement group_id="O5" value="0.00" spread="0.000"/>
                    <measurement group_id="O6" value="-0.67" spread="3.152"/>
                    <measurement group_id="O7" value="-0.59" spread="4.426"/>
                    <measurement group_id="O8" value="-1.77" spread="2.301"/>
                    <measurement group_id="O9" value="-2.02" spread="3.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BM: Change at Week 16 (n=1,3,2,3,4,22,24,16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="-2.51" spread="3.716"/>
                    <measurement group_id="O3" value="1.72" spread="0.596"/>
                    <measurement group_id="O4" value="-0.12" spread="2.324"/>
                    <measurement group_id="O5" value="-2.45" spread="2.208"/>
                    <measurement group_id="O6" value="-1.81" spread="3.278"/>
                    <measurement group_id="O7" value="-2.17" spread="3.523"/>
                    <measurement group_id="O8" value="-1.68" spread="2.899"/>
                    <measurement group_id="O9" value="-1.86" spread="3.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB: Baseline (n=2,3,2,4,6,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.061"/>
                    <measurement group_id="O2" value="1.17" spread="1.258"/>
                    <measurement group_id="O3" value="1.00" spread="1.414"/>
                    <measurement group_id="O4" value="1.00" spread="0.816"/>
                    <measurement group_id="O5" value="1.33" spread="0.816"/>
                    <measurement group_id="O6" value="1.20" spread="0.974"/>
                    <measurement group_id="O7" value="1.46" spread="0.978"/>
                    <measurement group_id="O8" value="0.97" spread="0.950"/>
                    <measurement group_id="O9" value="1.05" spread="0.820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB: Change at Week 1 (n=2,3,2,4,5,23,25,19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.253"/>
                    <measurement group_id="O2" value="-1.00" spread="1.167"/>
                    <measurement group_id="O3" value="-0.33" spread="0.471"/>
                    <measurement group_id="O4" value="-0.12" spread="0.158"/>
                    <measurement group_id="O5" value="-0.30" spread="0.415"/>
                    <measurement group_id="O6" value="-0.36" spread="0.697"/>
                    <measurement group_id="O7" value="-0.24" spread="0.605"/>
                    <measurement group_id="O8" value="-0.05" spread="0.574"/>
                    <measurement group_id="O9" value="-0.10" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB: Change at Week 4 (n=2,2,2,3,5,23,23,16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.354"/>
                    <measurement group_id="O2" value="-0.29" spread="1.010"/>
                    <measurement group_id="O3" value="-0.25" spread="0.354"/>
                    <measurement group_id="O4" value="0.14" spread="0.378"/>
                    <measurement group_id="O5" value="-0.71" spread="0.990"/>
                    <measurement group_id="O6" value="-0.34" spread="0.883"/>
                    <measurement group_id="O7" value="-0.47" spread="0.840"/>
                    <measurement group_id="O8" value="-0.27" spread="0.738"/>
                    <measurement group_id="O9" value="-0.26" spread="0.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB: Change at Week 8 (n=2,3,2,3,6,22,23,13,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.354"/>
                    <measurement group_id="O2" value="-0.50" spread="0.500"/>
                    <measurement group_id="O3" value="0.00" spread="0.000"/>
                    <measurement group_id="O4" value="0.33" spread="0.577"/>
                    <measurement group_id="O5" value="-0.47" spread="1.035"/>
                    <measurement group_id="O6" value="-0.40" spread="0.709"/>
                    <measurement group_id="O7" value="-0.51" spread="0.805"/>
                    <measurement group_id="O8" value="-0.19" spread="0.997"/>
                    <measurement group_id="O9" value="-0.51" spread="0.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB: Change at Week 12 (n=1,1,1,2,2,21,25,16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="0.00">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O3" value="0.00">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O4" value="0.00" spread="0.000"/>
                    <measurement group_id="O5" value="0.00" spread="0.000"/>
                    <measurement group_id="O6" value="-0.60" spread="0.792"/>
                    <measurement group_id="O7" value="-0.49" spread="1.084"/>
                    <measurement group_id="O8" value="-0.48" spread="0.829"/>
                    <measurement group_id="O9" value="-0.39" spread="0.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RB: Change at Week 16 (n=1,3,2,3,4,22,24,16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00">No standard deviation was calculated as only 1 participant was analyzed.</measurement>
                    <measurement group_id="O2" value="-1.17" spread="1.258"/>
                    <measurement group_id="O3" value="-0.10" spread="0.141"/>
                    <measurement group_id="O4" value="0.33" spread="0.577"/>
                    <measurement group_id="O5" value="-1.14" spread="0.865"/>
                    <measurement group_id="O6" value="-0.41" spread="0.936"/>
                    <measurement group_id="O7" value="-0.86" spread="1.106"/>
                    <measurement group_id="O8" value="-0.41" spread="0.838"/>
                    <measurement group_id="O9" value="-0.39" spread="0.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 4)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.144</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Pooled MultiStem versus Pooled Placebo (Week 8)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.158</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.213</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.209</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 12)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.226</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.234</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 MP versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.231</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Cohort 3 PM versus Cohort 3 PP (Week 16)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM using data up to Week 16</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.250</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 28 days after last study drug administration.</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another, or 1 participant may have experienced both an AE and SAE during the study. All treated participants were included in the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Placebo, MultiStem 300</title>
          <description>Participants received a single dose (Day 1) or 3 doses (Day 1, Week 1, Week 2) of placebo infusion, followed by a single dose of MultiStem 300 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: Placebo, MultiStem 750</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1: MultiStem 300, Placebo</title>
          <description>Participants received a single dose of MultiStem 300 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1: MultiStem 300 (x3), Placebo</title>
          <description>Participants received up to 3 doses of MultiStem 300 Million Cells infusion (Day 1, Week, Week 2), followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 2: MultiStem 750, Placebo</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3: MultiStem 750, MultiStem 750</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 3: MultiStem 750, Placebo</title>
          <description>Participants received a single dose of MultiStem 750 Million Cells infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 3: Placebo, MultiStem 750</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of MultiStem 750 Million Cells infusion at Week 8.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 3: Placebo, Placebo</title>
          <description>Participants received a single dose of placebo infusion on Day 1, followed by a single dose of placebo infusion at Week 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pelvic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Superior sagittal sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Painful defaecation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Perianal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Antibody test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bacterial test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cold agglutinins</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Ileostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

